Fundz

Northwest Biotherapeutics Inc reported raising $52,000 in an initial SEC Form D filing

PUBLIC · NWBOMay 17, 2017

Amount Raised

$52,000

$52,000 sold, per SEC Form D (first sale May 17, 2017)

Round Type

Pre-Seed

BethesdaBiotechnologyHealthcareresearch

Who else raised in Healthcare and research around the same time

Companies in the same sectors as Northwest Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Outset Medical raised $4.3M (Seed) on June 30, 2017.
  • Eton Pharmaceuticals raised $20M on June 28, 2017.
  • Avitide, Inc. raised $12M on June 27, 2017.
  • Nacuity Pharmaceuticals, Inc. raised $7.3M on June 27, 2017.
  • Bigfoot Biomedical, Inc. raised $5.2M on June 21, 2017.
  • Marina Biotech, Inc. raised $224K (Seed) on June 20, 2017.

Who to call at Northwest Biotherapeutics, and when

A new round usually means Northwest Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Northwest Biotherapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Northwest Biotherapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Northwest Biotherapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Northwest Biotherapeutics

Location

4800 MONTGOMERY LANE,

Bethesda, Maryland, United States

About

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." This Phase III trial reached data lock and the Company is actively continuing to move toward announcement of top line data. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Northwest Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

5 contacts
Verified contactsLinda P., Chief Executive Officer hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Northwest Biotherapeutics's next move

See what Strategic adds

Northwest Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.